E2f3a and E2f3b make overlapping but different contributions to total E2f3 activity

Oncogene

Volumn 27, Issue 51, 2008, Pages 6561-6570

  Danielian, P S ^a   Friesenhahn, L B ^a   Faust, A M ^a,c   West, J C ^a   Caron, A M ^a   Bronson, R T ^b   Lees, J A ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b TUFTS UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Arf; Cell cycle; E2f1; E2f3

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR; TRANSCRIPTION FACTOR E2F3; TRANSCRIPTION FACTOR E2F3A; TRANSCRIPTION FACTOR E2F3B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; GENE INACTIVATION; GENE MUTATION; GENE REPRESSION; GENE TARGETING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING;

ADP-RIBOSYLATION FACTORS; ANIMALS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; E2F1 TRANSCRIPTION FACTOR; E2F3 TRANSCRIPTION FACTOR; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; SIGNAL TRANSDUCTION;

MURINAE; MUS;

EID: 55249122429     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.253     Document Type: Article

References (27)

1. Adams MR, Sears R, Nuckolls F, Leone G, Nevins JR. (2000). Complex transcriptional regulatory mechanisms control expression of the E2F3 locus. Mol Cell Biol 20: 3633-3639.
2. Aslanian A, Iaquinta PJ, Verona R, Lees JA. (2004). Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics. Genes Dev 18: 1413-1422.
3. Attwooll C, Lazzerini Denchi E, Helin K. (2004). The E2F family: specific functions and overlapping interests. EMBO J 23: 4709-4716.
4. Berthet C, Kaldis P. (2007). Cell-specific responses to loss of cyclin-dependent kinases. Oncogene 26: 4469-4477.
5. Blais A, Dynlacht BD. (2007). E2F-associated chromatin modifiers and cell cycle control. Curr Opin Cell Biol 19: 658-662.
6. Cloud JE, Rogers C, Reza TL, Ziebold U, Stone JR, Picard MH et al. (2002). Mutant mouse models reveal the relative roles of E2F1 and E2F3 in vivo. Mol Cell Biol 22: 2663-2672.
7. Cooper CS, Nicholson AG, Foster C, Dodson A, Edwards S, Fletcher A et al. (2006). Nuclear overexpression of the E2F3 transcription factor in human lung cancer. Lung Cancer 54: 155-162.
8. Courel M, Friesenhahn L, Lees JA. (2008). E2f6 and Bmi1 cooperate in axial skeletal development. Dev Dyn 237: 1232-1242.
9. Danielian PS, Bender Kim CF, Caron AM, Vasile E, Bronson RT, Lees JA. (2007). E2f4 is required for normal development of the airway epithelium. Dev Biol 305: 564-576.
10. Dimova DK, Dyson NJ. (2005). The E2F transcriptional network: old acquaintances with new faces. Oncogene 24: 2810-2826.
11. Feber A, Clark J, Goodwin G, Dodson AR, Smith PH, Fletcher A et al. (2004). Amplification and overexpression of E2F3 in human bladder cancer. Oncogene 23: 1627-1630.
12. Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin Jr WG, Livingston DM et al. (1996). E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 85: 549-561.
13. Foster CS, Falconer A, Dodson AR, Norman AR, Dennis N, Fletcher A et al. (2004). Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 23: 5871-5879.
14. He Y, Armanious MK, Thomas MJ, Cress WD. (2000). Identification of E2F-3B, an alternative form of E2F-3 lacking a conserved N-terminal region. Oncogene 19: 3422-3433.
15. Humbert PO, Verona R, Trimarchi JM, Rogers C, Dandapani S, Lees JA. (2000). E2f3 is critical for normal cellular proliferation. Genes Dev 14: 690-703.
16. Hurst CD, Tomlinson DC, Williams SV, Platt FM, Knowles MA. (2008). Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification. Oncogene 27: 2716-2727.
17. Janumyan YM, Sansam CG, Chattopadhyay A, Cheng N, Soucie EL, Penn LZ et al. (2003). Bcl-xL/Bcl-2 coordinately regulates apoptosis, cell cycle arrest and cell cycle entry. EMBO J 22: 5459-5470.
18. Leone G, Nuckolls F, Ishida S, Adams M, Sears R, Jakoi L et al. (2000). Identification of a novel E2F3 product suggests a mechanism for determining specificity of repression by Rb proteins. Mol Cell Biol 20: 3626-3632.
19. Oeggerli M, Schraml P, Ruiz C, Bloch M, Novotny H, Mirlacher M et al. (2006). E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer. Oncogene 25: 6538-6543.
20. Oeggerli M, Tomovska S, Schraml P, Calvano-Forte D, Schafroth S, Simon R et al. (2004). E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene 23: 5616-5623.
21. Orlic M, Spencer CE, Wang L, Gallie BL. (2006). Expression analysis of 6p22 genomic gain in retinoblastoma. Genes Chromosomes Cancer 45: 72-82.
22. Parisi T, Yuan TL, Faust AM, Caron AM, Bronson R, Lees JA. (2007). Selective requirements for E2f3 in the development and tumorigenicity of Rb-deficient chimeric tissues. Mol Cell Biol 27: 2283-2293.
23. Sharma N, Timmers C, Trikha P, Saavedra HI, Obery A, Leone G. (2006). Control of the p53-p21CIP1 Axis by E2f1, E2f2, and E2f3 is essential for G1/S progression and cellular transformation. J Biol Chem 281: 36124-36131.
24. Timmers C, Sharma N, Opavsky R, Maiti B, Wu L, Wu J et al. (2007). E2f1, E2f2, and E2f3 control E2F target expression and cellular proliferation via a p53-dependent negative feedback loop. Mol Cell Biol 27: 65-78.
25. Trimarchi JM, Lees JA. (2002). Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 3: 11-20.
26. Wu L, Timmers C, Maiti B, Saavedra HI, Sang L, Chong GT et al. (2001). The E2F1-3 transcription factors are essential for cellular proliferation. Nature 414: 457-462.
27. Ziebold U, Lee EY, Bronson RT, Lees JA. (2003). E2F3 loss has opposing effects on different pRB-deficient tumors, resulting in suppression of pituitary tumors but metastasis of medullary thyroid carcinomas. Mol Cell Biol 23: 6542-6552.